

# Leonard Pieter Bokhorst

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7733618/publications.pdf>

Version: 2024-02-01

19  
papers

1,208  
citations

759233

12  
h-index

794594

19  
g-index

22  
all docs

22  
docs citations

22  
times ranked

1817  
citing authors

#	ARTICLE	IF	CITATIONS
1	Characteristics of Prostate Cancer Found at Fifth Screening in the European Randomized Study of Screening for Prostate Cancer Rotterdam: Can We Selectively Detect High-grade Prostate Cancer with Upfront Multivariable Risk Stratification and Magnetic Resonance Imaging?. <i>European Urology</i> , 2018, 73, 343-350.	1.9	19
2	Long-term follow-up after active surveillance or curative treatment: quality-of-life outcomes of men with low-risk prostate cancer. <i>Quality of Life Research</i> , 2017, 26, 1635-1645.	3.1	24
3	Biopsy undergrading in men with Gleason score $\geq 6$ and fatal prostate cancer in the European Randomized study of Screening for Prostate Cancer Rotterdam. <i>International Journal of Urology</i> , 2017, 24, 281-286.	1.0	4
4	Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer. <i>BJU International</i> , 2017, 120, 511-519.	2.5	67
5	Effect of pathologic revision and Ki67 and ERG immunohistochemistry on predicting radical prostatectomy outcome in men initially on active surveillance. <i>Prostate</i> , 2017, 77, 1137-1143.	2.3	5
6	Correlation between stage shift and differences in mortality in the European Randomised study of Screening for Prostate Cancer (ERSPC). <i>BJU International</i> , 2016, 118, 677-680.	2.5	9
7	A Decade of Active Surveillance in the PRIAS Study: An Update and Evaluation of the Criteria Used to Recommend a Switch to Active Treatment. <i>European Urology</i> , 2016, 70, 954-960.	1.9	290
8	Complications after prostate biopsies in men on active surveillance and its effects on receiving further biopsies in the Prostate Cancer Research International: Active Surveillance (PRIAS) study. <i>BJU International</i> , 2016, 118, 366-371.	2.5	51
9	Risk-based Patient Selection for Magnetic Resonance Imaging-targeted Prostate Biopsy after Negative Transrectal Ultrasound-guided Random Biopsy Avoids Unnecessary Magnetic Resonance Imaging Scans. <i>European Urology</i> , 2016, 69, 1129-1134.	1.9	54
10	Active surveillance for prostate cancer: a narrative review of clinical guidelines. <i>Nature Reviews Urology</i> , 2016, 13, 151-167.	3.8	139
11	Rule-based versus probabilistic selection for active surveillance using three definitions of insignificant prostate cancer. <i>World Journal of Urology</i> , 2016, 34, 253-260.	2.2	11
12	Magnetic Resonance Imaging in Active Surveillance of Prostate Cancer: A Systematic Review. <i>European Urology</i> , 2015, 67, 627-636.	1.9	284
13	Compliance Rates with the Prostate Cancer Research International Active Surveillance (PRIAS) Protocol and Disease Reclassification in Noncompliers. <i>European Urology</i> , 2015, 68, 814-821.	1.9	116
14	Differences in Treatment and Outcome After Treatment with Curative Intent in the Screening and Control Arms of the ERSPC Rotterdam. <i>European Urology</i> , 2015, 68, 179-182.	1.9	14
15	Ethnicity and prostate cancer: the way to solve the screening problem?. <i>BMC Medicine</i> , 2015, 13, 179.	5.5	5
16	The ProtecT trial: what can we expect?. <i>Lancet Oncology</i> , The, 2014, 15, 1046-1047.	10.7	5
17	Prostate-specific Antigen-Based Prostate Cancer Screening: Reduction of Prostate Cancer Mortality After Correction for Nonattendance and Contamination in the Rotterdam Section of the European Randomized Study of Screening for Prostate Cancer. <i>European Urology</i> , 2014, 65, 329-336.	1.9	72
18	Reply from Authors re: Michael Baum. Screening for Prostate Cancer: Can We Learn from the Mistakes of the Breast Screening Experience? <i>Eur Urol</i> 2013;64:540-1. <i>European Urology</i> , 2013, 64, 541-543.	1.9	3

#	ARTICLE	IF	CITATIONS
19	Positive predictive value of prostate biopsy indicated by prostate-specific antigen-based prostate cancer screening: trends over time in a European randomized trial*. BJU International, 2012, 110, 1654-1660.	2.5	36